Trial Profile
A phase 3 trial of cytisine for the treatment of smoking cessation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2017
Price :
$35
*
At a glance
- Drugs Cytisinicline (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
- Acronyms TASC
- 10 Aug 2017 According to an Achieve Life Sciences media release, conceived by Professor Robert West at University College London and funded by the U.K. National Prevention Research Initiative.
- 08 Mar 2017 According to an OncoGenex Pharmaceuticals media release, this trial was conducted by University College London.
- 28 Jul 2015 New trial record